CNS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

CNS Pharmaceuticals

01/04/2025 09:34

CNS Pharmaceuticals Inc CNSP.OQ reported a quarterly adjusted loss of $9.25​​ per share for the quarter ended December 31.  The lone analyst forecast for the quarter was for a loss of $9.66 per share.

Reported revenue was zero​; analysts expected zero.

CNS Pharmaceuticals Inc's reported EPS for the quarter was a loss of $9.25​.

The company reported a quarterly loss of $3.18 million.

CNS Pharmaceuticals Inc shares had held steady so far this quarter and lost 77.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 61% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "hold."

Wall Street's median 12-month price target for CNS Pharmaceuticals Inc is $200.00

This summary was machine generated from LSEG data April 1 at 08:34 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-9.66
-9.25
Beat
Sep. 30 2024
-5.00
-12.50
Missed